# Toursun Synbio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/toursun-synbio

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Latest round: Angel (Sep 3, 2025)
- Investors on record: 3

## About

Based in Shanghai, China, and founded in 2023, Toursun Synbio is a biotechnology company focusing on artificial intelligence protein design services. The core team comes from Johns Hopkins University, Tsinghua University, and the Chinese Academy of Sciences. The founder and CEO, Yuguang Wang, graduated from the University of South Wales and is currently an associate professor at Shanghai Jiao Tong University. In February 2024, Toursun Synbio closed an angel funding. In September 2025, it closed an angel+ funding from new investor Shanghai Angel Group and returning investor Chengmei Capital.

Toursun Synbio is committed to the research and development of the AI protein design platform ProteinEngine, which can accelerate enzyme modification and sequence design processes. It has been applied in multiple fields such as food, medicine, the chemical industry, and medical aesthetics. The company has made progress in product transformation in P450 protein, vanillin catalytic enzyme, vaccine antibody, etc.

The company generates revenue by providing artificial intelligence protein design.

The company plans to use the proceeds from the angel+ round into further development of its AI protein design platform, enhance product innovation, expand customer service capabilities and support industry upgrading.

## Funding rounds

- Angel, Sep 3, 2025 — Chengmei Capital, Shanghai Angel Group
- Angel, Feb 29, 2024 — Chengmei Capital, Photon Core Valley Technology (Wuxi)

## Investors

- Chengmei Capital (https://capitalatlas.ai/funds/chengmei-capital) — Angel
- Photon Core Valley Technology (Wuxi) — Angel
- Shanghai Angel Group — Angel